PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF
Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amo...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
24.08.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.
L'invention concerne un inhibiteur de AXL, Mer et/ou c-Met de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci : Formule (I), dans laquelle R1, R2, R3, G et Q sont décrits dans la description. L'invention concerne en outre une méthode de traitement ou de prévention d'une maladie médiée par AXL, Mer et/ou c-Met à l'aide d'une quantité efficace du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. Lorsque AXL, MER et/ou c-Met sont inhibé, le composé ou un sel pharmaceutiquement acceptable de celui-ci peut resensibiliser des cellules cancéreuses, telles que des cellules du cancer du poumon non à petites cellules, qui ont fait l'objet d'une croissance résistante à un agent anticancéreux. |
---|---|
Bibliography: | Application Number: WO2023IB50812 |